Investor Presentaiton
Segment (Healthcare)
Chromatography: Expand sales for diabetes and the rapidly expanding obesity medications
utilizing the enhanced capacity of Amagasaki plant, focus on the sales of a new lineup of
packed columns
APIs and their intermediates: Increase orders due to new facilities (PI-3) at Matsuyama Plant
Net sales
Operating income
(Millions of yen)
Variance (Operating income, YoY)
11,600
10,275
Sales
8,224
3,375
5,350
Production
and sales
volume
+1.2
(Billions of yen)
Fixed costs
(0.5)
4,615
Unit
Feedstock
price
cost
+0.1
(0.1)
FY2021 X
FY2022 X
FY2023
Forecast
4.6
Net sales (up ¥1.3 billion YoY)
Chromatography*
APIs and Their Intermediates
+0.8
+0.5
FY2022 *
* Pharmaceutical purification materials (silica gel), analytical equipment, packed columns
*Figures by segment for FY2021 and FY2022 are approximate figures reclassified into new segments
Something Better with Chemicals
5.3
FY2023
Forecast
OSAKA SODA
15View entire presentation